EVALUATION OF TREATMENT OUTCOMES OF STAGE IIIB–IV NON- SMALL CELL LUNG CANCER WITH EGFR MUTATIONS USING FIRST-GENERATION TYROSINE KINASE INHIBITORS AT CAN THO CITY IN 2020 - 2023
Main Article Content
Abstract
Background: Advanced non-small cell lung cancer (NSCLC) is often diagnosed late, with varied symptoms and distant metastases, leading to poor outcomes. EGFR mutations are common in Asian patients (10–50%) and respond well to tyrosine kinase inhibitors (TKIs). First-generation TKIs can improve survival and quality of life with good tolerability. Objectives: To evaluate clinical characteristics, treatment outcomes, and related factors in stage IIIB–IV NSCLC patients treated with first-generation TKIs in Can Tho (2020–2023). Materials and methods: A total of 58 patients with stage IIIB–IV EGFR-mutant NSCLC received first-generation TKIs at Can Tho Oncology Hospital and Can Tho University of Medicine and Pharmacy Hospital. Results: The mean age was 63.6 years, with a female predominance. Common symptoms included chest pain and dyspnea. Over half had metastases to ≥2 organs, mainly bone and pleura. Exon 19 deletion (60.4%) and L858R mutation (36.2%) were predominant. The overall response rate was 71.5%, and the disease control rate was 95.3%. Median progression-free survival (PFS) and overall survival (OS) were 16.1 and 21.2 months. Mutation type and skin rash were associated with survival outcomes. Adverse events were mostly mild, including rash and diarrhea. Conclusion: First-generation TKIs are effective, improve survival and quality of life, and are well tolerated in advanced EGFR-mutant NSCLC.
Keywords
Non-small cell lung cancer, EGFR, first-generation TKIs
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Đỗ M.L., Thịnh, T. H., Hiếu, N. V. Đánh giá kết quả thuốc Erlotinib trong điều trị bước một ung thư phổi không tế bào nhỏ có đột biến EGFR. Tạp Chí Nghiên cứu Y học. 2021. 137(1), 76-83. DOI:10.52852/tcncyh.v137i1.20.
3. Lê Thu Hà. Đánh giá hiệu quả thuốc Erlotinib trong điều trị ung thư phổi biểu mô tuyến giai đoạn muộn. Trường Đại học Y Hà Nội. 2017. 180.
4. Mok T.S., Wu Y.L., Thongprasert S. and et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma (IPASS). New England Journal of Medicine. 2009. 361(10), 947–957. DOI: 10.1056/nejmoa0810699.
5. Maemondo M., Inoue A., Kobayashi K. and et al. Gefitinib or chemotherapy for non–smallcell lung cancer with mutated EGFR (NEJ002). New England Journal of Medicine. 2010. 362(25), 2380–2388. DOI:10.1056/nejmoa0909530.
6. Zhou C., Wu Y.L., Chen G., and et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation–positive non–small-cell lung cancer (OPTIMAL, CTONG-0802). Lancet Oncology. 2011. 12(8), 735–742. DOI: 10.1016/s14702045(11)70184-x.
7. Wu YL, Zhou C, Liam CK, Wu G, Liu X, and et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015. 26(9):1883-1889. DOI: 10.1093/annonc/mdv270.
8. Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, and et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017. 116(5):568-574. DOI: 10.1038/bjc.2016.456.
9. Van Luan P, Tien ND, Hai NM, Tien ND, Duyen TT. Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations. Ther Adv Med Oncol. 2021. 13:1758835921992977. DOI: 10.1177/1758835921992977.
10. Nguyen KT, Pham TH, Ngo VL, Bui VT, Nguyen VN, Nguyen TPT, Nguyen TKH, Nguyen TTV. Tyrosine kinase inhibitors in first-line treatment of advanced NSCLC with epidermal growth factor receptor mutations: Real-world data from Vietnam. Oncol Res. 2025. 33(7):16671677. DOI: 10.32604/or.2025.061905.